Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Amid New Phase 3 Trial
Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Amid New Phase 3 Trial Yahoo Finance
Covered in this story
Analyst targets on Moderna
- Citi: $193 → $80 by Sep 2027 · Sell via 247wallst.com
- Rothschild & Co Redburn: $149 → $81 by Sep 2027 · Sell via Investing.com
- Morgan Stanley: $174 → $89 by Aug 2027 · Equalweight via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MRNA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Moderna →Summary aggregated from Yahoo Finance's public RSS feed. The full reporting belongs to Yahoo Finance — please read it on their site.